A Phase 1 Study of LY4050784 in People With Advanced Solid Tumors

Full Title

Purpose

Researchers want to find the best dose of LY4050784 to treat advanced solid tumors. The people in this study have cancer that cannot be cured with standard therapies. Their tumors also have a mutation (change) in the SMARCA4 and/or BRG1 genes, which play a role in cancer growth.

LY4050784 targets cancer cells that make a gene called SMARCA2/BRM. The molecules of these drugs are small enough to enter cells easily. Once inside the cells, they can affect other molecules, such as proteins, and cause cancer cells to die. LY4050784 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a metastatic or locally advanced solid tumor that keeps growing after treatment or cannot be treated using standard therapies.
• Have a solid tumor with a SMARCA4 and/or BRG1 mutation.
• Have recovered from the serious side effects of prior therapies before taking LY4050784.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call 646-888-4226.